Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in pulmonary arterial hypertension

Saturday, June 29, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). It highlights the potential benefits of seralutinib as a treatment option, emphasizing its relevance in improving patient outcomes. The findings may contribute to advancing therapeutic strategies for PAH.
Price reaction · baseline $0.9009 (2024-06-28 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close
+5.2%
day 1
+6.5%
day 3 · peak
+19.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Inhaled seralutinib shows promise for improving right heart function.
  • The study focuses on a critical aspect of pulmonary arterial hypertension.
  • Potential to enhance treatment options for patients with PAH.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Effects of inhaled seralutinib on right ventricular-pulmonary arterial coupling and right heart function in pulmonary arterial hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the focus of the study on seralutinib?

The study examines the effects of inhaled seralutinib on right heart function in PAH.

How does seralutinib affect right ventricular coupling?

Inhaled seralutinib may improve right ventricular-pulmonary arterial coupling in PAH patients.

What condition is seralutinib targeting?

Seralutinib is targeting pulmonary arterial hypertension (PAH).

What are the potential benefits of seralutinib?

Seralutinib may enhance treatment options and improve patient outcomes in PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension right heart function PAH
Last updated: Jun 29, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →